ASX:AYAHealthcare Services
How Investors May Respond To Artrya (ASX:AYA) Raising A$80 Million for US FDA-Approved Salix Expansion
Artrya recently completed a major capital raise of A$80 million through follow-on equity offerings, aimed at supporting its US expansion after securing FDA approval for its AI-driven Salix coronary plaque detection device.
This development underscores growing investor confidence in Artrya’s efforts to commercialize advanced medical technology in the lucrative US healthcare market.
We'll explore how the FDA-approved rollout of Salix in the US contributes to Artrya's broader investment...